Navigation Links
NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil®
Date:6/5/2011

4

4

4Previous Platinum Regimens  1

13%

35%

24%  2

56%

24%

39%  3

25%

18%

21%  4+

6%

24%

15%Prior bevacizumab

6%

24%

15%Prior gemcitabine

56%

59%

58%Prior taxane

100%

100%

100%TABLE 2. Efficacy Results: Objective Response Rates by RECIST and GCIG in Subpopulation Receiving Prior Treatment with PLDNKTR-102NKTR-102145 mg/m2  q14d145 mg/m2q21dRECISTN (evaluable)16

14Confirmed + Unconfirmed

4 (25%)

4 (29%)Confirmed

3 (19%)

3 (21%)Duration of Confirmed Response (months, range)

4.2 (3-14)

4.4 (3-9)GCIGN (evaluable)

16

17Confirmed + Unconfirmed

8 (50%)

6 (35%)Confirmed

6 (38%)

6 (35%)CA-125N (evaluable)

15

14Confirmed

6 (40%)

5 (36%)*Only patients with measurable disease/CA-125 at baseline were considered evaluable.TABLE 3. Safety Results in Subpopulation Receiving Prior Treatment with PLDMost Common Drug-related Grade 3 and 4

Adverse Events > 5% or event of interest

N (%) NKTR-102

145 mg/m2

q14d

N=16

NKTR-102

145 mg/m2

q21d

N=17Grade 3

Grade 4

Grade 3

Grade 4Diarrhea

5 (31%)

0

3 (18%)

0Hypokalemia

5 (31%)

1 (6%)

0

0Nausea

5 (31%)

0

1 (6%)

0Dehydration

3 (19%)

0

1 (6%)

0Fatigue

1 (6%)

0

3 (18%)

0Vomiting

4 (25%)

0

0

0Neutropenia

1 (6%)

0

1 (6%)

1 (6%)Anaemia

2 (12.5%)

0

0

0Decreased appetite

1 (6%)

0

1 (6%)

0Hyponatraemia

2 (13%)

0

0

0Lymphophenia

1 (6%)

0

1 (6%)

0Note: There wa
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
2. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
3. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
4. NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
5. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
8. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
9. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
10. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
11. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... May 1, 2015   Heska Corporation (NASDAQ: ... a provider of advanced veterinary diagnostic and other specialty ... Executive Chair, will present at the 16th Annual B. Riley ... 13, 2015. The conference will be held May 12-14, 2015 ... Heska management will be available during the day on ...
(Date:5/1/2015)... , May 1, 2015 Braeburn ... its current therapeutic focus beyond addiction and ... psychiatric disorders. Braeburn has acquired an implantable, ... antipsychotic risperidone for treatment of schizophrenia from ... acquires global rights to other potential applications ...
(Date:5/1/2015)...  Boston Scientific Corporation (NYSE: BSX ) is ... long-term growth strategies at a meeting with the investment ... . President and Chief Executive Officer Mike Mahoney ... to bring forward meaningful innovation to transform patient care, ... value. "We are focused on addressing ...
Breaking Medicine Technology:Heska to Present at the 16th Annual B. Riley & Co. Investor Conference 2Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 2Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 3Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 4Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 2Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 3Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 4Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 5Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 6Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 7
... LYNDHURST, N.J., Aug. 30 A molecular,diagnostic ... 85,developmental disorders affecting children now is commercially ... testing and,reimbursement by leading health plans across ... ), the nation,s leading provider of diagnostic,testing, ...
... Cadence Pharmaceuticals,Inc. (Nasdaq: CADX ), ... commercializing proprietary product candidates principally,for use in ... completed patient,enrollment in a pivotal Phase III ... intravenous acetaminophen (IV,acetaminophen), for the treatment of ...
Cached Medicine Technology:Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children 2Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children 3Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children 4Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule 2Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule 3Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule 4Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule 5
(Date:5/2/2015)... Peachtree Audio ” was featured on NewsWatch as part ... and coolest technology products available to consumers. Scott Steinberg, ... the review and shared with viewers how this is ... important part of people’s lives – and as such, ... Peachtree Audio does just that with high-end audio equipment ...
(Date:5/2/2015)... Kare Visits LLC. launched in Chicago in response ... Kare Visits offers relief for caregivers by visiting loved ones ... According to the Caregiver Action Network, eight in ten caregivers ... a week caring for an elderly or disabled loved one. ... nurse, a caregiver is now empowered to schedule an on ...
(Date:5/2/2015)... ZoomCare, the Portland-based innovator of on-demand healthcare ... its new healthcare insurance to individuals and small businesses ... System is the nation’s first health insurance system built ... Personal Health Insurance was ZoomCare’s first such filing including ... to review and regulation by the Oregon Insurance Division. ...
(Date:5/1/2015)... IDLife LLC, a health and wellness company headquartered ... of its newest partner and fitness celebrity, Jen Widerstrom. ... up in gymnastics and competitive diving, but truly found ... trainer and helping others achieve their fitness aspirations. Jen ... highlighting her stunning physique and unique training techniques. ...
(Date:5/1/2015)... Pioneer Millworks, the largest reclaimed wood company in ... wood products at the 27th annual International Contemporary Furniture ... this May. Their newest offerings, Vat 35, Mushroom Boards, ... color to North America's platform for global design. ... in the design world and we're excited to share ...
Breaking Medicine News(10 mins):Health News:Affordable High-End Audio Equipment was Featured on NewsWatch Television 2Health News:Chicagoan Seeks to Transform Industry by Launching an Innovative Elderly Care Solution 2Health News:ZoomCare Applies to be on Oregon Exchange 2Health News:IDLife LLC Announces New Partnership with Fitness Celebrity, Jen Widerstrom 2Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 2Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 3
... of students nationwide prepare to leave high school, a UC ... the medical journal Pediatrics shows a clear link ... as kindergarten and lower high school test scores. , ... they start school had the strongest negative effect on how ...
... now have a new and simple way to diagnose ... to David Kaelber, M.D., Ph.D., M.P.H., MetroHealth System pediatrician, ... Reserve University School of Medicine researcher and faculty member. ... of cases of prehypertension in children and adolescents go ...
... prior research on the cholesterol-lowering drugs , , MONDAY, May 25 ... reduces the risk of a second stroke, new research shows. ... strokes found a 35 percent lower incidence of second strokes ... took statins compared to those who didn,t, according to a ...
... for bulk vaccine valued at $190 million -SWIFTWATER, Pa. and ... of the sanofi-aventis Group (EURONEXT: SAN and NYSE: ... what is expected to be a series of orders from ... commence production of a vaccine to help protect against the ...
... The general health of toddlers in,the SAR has room ... Hong,Kong Institute of Asia-Pacific Studies at the Chinese ... today to announce the results, a researcher from,CUHK as ... registered dietician,all agreed that, based on the survey, many ...
... to manufacturers by month,s end, CDC says , , SUNDAY, ... progress towards a viable H1N1 swine flu vaccine this ... Control and Prevention saying they had two promising candidate ... CDC received, from one institution, a candidate vaccine virus," ...
Cached Medicine News:Health News:Poor attention in kindergarten predicts lower high school test scores, UC Davis researchers find 2Health News:Poor attention in kindergarten predicts lower high school test scores, UC Davis researchers find 3Health News:Poor attention in kindergarten predicts lower high school test scores, UC Davis researchers find 4Health News:Pediatrician creates easier way to identify kids' high BP 2Health News:Statins Can Help Prevent Second Stroke 2Health News:Statins Can Help Prevent Second Stroke 3Health News:Sanofi Pasteur Receives Order from U.S. Government to Produce New Influenza A(H1N1) Vaccine 2Health News:Sanofi Pasteur Receives Order from U.S. Government to Produce New Influenza A(H1N1) Vaccine 3Health News:Sanofi Pasteur Receives Order from U.S. Government to Produce New Influenza A(H1N1) Vaccine 4Health News:Sanofi Pasteur Receives Order from U.S. Government to Produce New Influenza A(H1N1) Vaccine 5Health News:CUHK Releases Results of 'Survey on Toddler Health in Hong Kong' 2Health News:CUHK Releases Results of 'Survey on Toddler Health in Hong Kong' 3Health News:CUHK Releases Results of 'Survey on Toddler Health in Hong Kong' 4Health News:U.S. Closer to Viable Swine Flu Shot 2Health News:U.S. Closer to Viable Swine Flu Shot 3Health News:U.S. Closer to Viable Swine Flu Shot 4Health News:U.S. Closer to Viable Swine Flu Shot 5Health News:U.S. Closer to Viable Swine Flu Shot 6Health News:U.S. Closer to Viable Swine Flu Shot 7Health News:U.S. Closer to Viable Swine Flu Shot 8Health News:U.S. Closer to Viable Swine Flu Shot 9Health News:U.S. Closer to Viable Swine Flu Shot 10Health News:U.S. Closer to Viable Swine Flu Shot 11Health News:U.S. Closer to Viable Swine Flu Shot 12Health News:U.S. Closer to Viable Swine Flu Shot 13
Round serrated handle, dull finish....
Cross action, round handle, maximum opening 2.8 mm....
Cross action, round handle, maximum opening 2.8 mm....
Cross action, round handle, maximum opening 2.8 mm....
Medicine Products: